These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30464404)

  • 1. Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy.
    Corado KC; Caplan MR; Daar ES
    Drug Des Devel Ther; 2018; 12():3731-3740. PubMed ID: 30464404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
    Llibre JM; Hung CC; Brinson C; Castelli F; Girard PM; Kahl LP; Blair EA; Angelis K; Wynne B; Vandermeulen K; Underwood M; Smith K; Gartland M; Aboud M
    Lancet; 2018 Mar; 391(10123):839-849. PubMed ID: 29310899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
    Cento V; Perno CF
    J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.
    Casado JL; Monsalvo M; Rojo AM; Fontecha M; Rodriguez-Sagrado MA
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):561-570. PubMed ID: 29775399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.
    Gantner P; Cuzin L; Allavena C; Cabie A; Pugliese P; Valantin MA; Bani-Sadr F; Joly V; Ferry T; Poizot-Martin I; Garraffo R; Peytavin G; Fafi-Kremer S; Rey D;
    HIV Med; 2017 Oct; 18(9):704-708. PubMed ID: 28444816
    [No Abstract]   [Full Text] [Related]  

  • 8. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.
    Ribera E
    AIDS Rev; 2018; 20(4):179-186. PubMed ID: 30548024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.
    Mehta R; Wolstenholme A; Di Lullo K; Fu C; Joshi S; Crauwels H; Givens N; Vanveggel S; Wynne B; Adkison K
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
    Boswell R; Foisy MM; Hughes CA
    Ann Pharmacother; 2018 Jul; 52(7):681-689. PubMed ID: 29442543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.
    Capetti AF; Astuti N; Cattaneo D; Rizzardini G
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1183-1192. PubMed ID: 28854832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults.
    Properzi M; Magro P; Castelli F; Quiros-Roldan E
    Expert Rev Anti Infect Ther; 2018 Dec; 16(12):877-887. PubMed ID: 30392419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.
    Hester EK; Astle K
    Ann Pharmacother; 2019 Aug; 53(8):860-866. PubMed ID: 30758229
    [No Abstract]   [Full Text] [Related]  

  • 14. Dolutegravir/Rilpivirine: A Review in HIV-1 Infection.
    Blair HA
    Drugs; 2018 Nov; 78(16):1741-1750. PubMed ID: 30406902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.
    Capetti AF; Cossu MV; Paladini L; Rizzardini G
    Expert Opin Pharmacother; 2018 Jan; 19(1):65-77. PubMed ID: 29246084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
    Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
    Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
    Bollen P; Reiss P; Schapiro J; Burger D
    Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barrier to Resistance of Dolutegravir in Two-Drug Combinations.
    Yoshinaga T; Miki S; Kawauchi-Miki S; Seki T; Fujiwara T
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection.
    Med Lett Drugs Ther; 2019 Aug; 61(1579):134-136. PubMed ID: 31581158
    [No Abstract]   [Full Text] [Related]  

  • 20. Dolutegravir-rilpivirine coformulation.
    Sun HY; Chang SY; Hung CC
    Curr Opin HIV AIDS; 2018 Jul; 13(4):320-325. PubMed ID: 29553948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.